AtriCure Reports Strong Q4 & Full-Year 2025 Results, Guides for Positive 2026 Net Income
ATRC sits 17% above its 52-week low of $28.29.
Summary
AtriCure, Inc. finalized strong Q4 and full-year 2025 financial results, reporting significant revenue growth and a return to profitability in Q4, while also issuing positive 2026 guidance including projected positive net income.
Key Events · Earnings and Guidance · ATRC
-
Strong Q4 2025 Performance
Reported worldwide revenue of $140.5 million, a 13.1% increase year-over-year, with net income of $1.8 million and adjusted EBITDA of $19.9 million.
-
Solid Full-Year 2025 Results
Achieved worldwide revenue of $534.5 million, up 14.9% year-over-year, significantly reducing net loss to $11.4 million and nearly doubling adjusted EBITDA to $61.8 million.
-
Positive 2026 Financial Guidance
Projected full-year 2026 revenue between $600 million and $610 million (12% to 14% growth), with adjusted EBITDA of $80 million to $82 million, and positive net income.
-
Operational Momentum
Growth was driven by expanding use of new products like cryoSPHERE MAX and AtriClip FLEX-Mini, and continued adoption of the EnCompass clamp.
Analysis · ATRC · Industrial Applications And Services
AtriCure, Inc. reported robust financial results for the fourth quarter and full-year 2025, confirming the strong preliminary figures announced on January 12, 2026. The company achieved significant revenue growth and a notable improvement in profitability, moving from a net loss in 2024 to positive net income in Q4 2025. Furthermore, management provided optimistic guidance for full-year 2026, projecting continued revenue growth and, critically, positive net income, signaling a strong operational turnaround and a clear path to sustained profitability. This performance, driven by expanding product adoption, positions the company favorably for future value creation.
At the time of this filing, ATRC was trading at $32.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $28.29 to $43.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.